Docetaxel Added to Anthracycline Regimens Benefits Patients with Highly Proliferative ER-Positive Breast Cancer

Article Information

DOI 
http://dx.doi.org/10.1177/155989771436009
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 MD Conference Express®

Author Information

  1. Nicola Parry
  1. Amir Sonnenblick, MD, PhD
    1. Free University of Brussels, Brussels, Belgium
View Full Text

Article usage

AbstractFullPDF
Apr 2015600
May 2015100
Jun 2015111
Jul 2015111
Aug 2015100
Sep 2015300
Oct 2015132
Nov 2015100
Total1554

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Docetaxel Added to Anthracycline Regimens Benefits Patients with Highly Proliferative ER-Positive Breast Cancer
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Oncology Clinical Trials
Breast Cancer
Adjuvant/Neoadjuvant Therapy
Oncology Clinical Trials
Oncology
Breast Cancer
Adjuvant/Neoadjuvant Therapy